260
Participants
Start Date
June 25, 2021
Primary Completion Date
October 31, 2025
Study Completion Date
December 31, 2030
Acalabrutinib
"Cohort A: 6 cycles of acalabrutinib-R-CHOP~Cohort B: 2 cycles of R-CHOP and 2 cycles of acalabrutinb-R-CHOP followed by 2 cycles of acalabrutinib single agent~Cohort C: 4 cycles of R-CHOP followed by 2 cycles of rituximab single agent~Cohort D: 6 cycles of R-CHOP~Rituximab 375 mg/m2 IV Day 1, cyclophosphamide 750 mg/m2 IV Day 1, doxorubicin 50 mg/m2 IV Day 1, vincristine 1.4 mg/m2 (maximum 2 mg) IV Day 1; prednisone 100 mg PO d1-5; Acalabrutinib 100 mg BID Day 1-21, cycles repeated every 21 days"
Hopitaux Universitaire de Genève (HUG), Geneva
Hopital Fribourgeois, Fribourg
Réseau Hospitalier Neuchâtelois (RHNe), Neuchâtel
St. Claraspital, Basel
Kantonsspital Baden (Baden/Brugg), Baden
Istituto Oncologico della Svizzera Italiana, Bellinzona
Kantonsspital Graubünden, Chur
UniversitätsSpital Zürich, Zurich
Kantonsspital Winterthur, Winterthur
Kantonsspital St. Gallen, Sankt Gallen
Azienda Ospedaliera Universitaria Maggiore della Carita di Novara, Novara
Ospedale Papa Giovanni XXIII, Bergamo
Policlinico Agostino Gemelli, Roma
Kantonsspital Aarau, Aarau
Inselspital, Bern, Bern
Centre Hospitalier Universitaire Vaudois, Lausanne
Kantonsspital Luzern, Luzerne
Kantonsspital Olten, Olten
City Hospital Triemli, Zurich
Swiss Cancer Institute
OTHER